Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
(UroToday.com) The 2025 SUO annual meeting featured a urothelial carcinoma session and a presentation by Dr. Reuben Ben-David discussing preoperative ctDNA predicting upstaging and recurrence in ...
Neoadjuvant intense androgen deprivation therapy (ADT) with androgen receptor signaling inhibitors (ARSIs) has shown pathologic complete responses (pCR) in prostate cancer (PCa), but long-term ...
(UroToday.com) At the metastatic prostate cancer session at the European Association of Urology 2021 Virtual Meeting, Dr. Simon Chowdhury presented results of outcomes in high and low-volume disease ...
(UroToday.com) The 2022 American Urological Association Annual Meeting included a prostate cancer session featuring work from Dr. Mohammad Siddiqui and colleagues presenting results of their study ...
ESMO 2024, Prostate Cancer, transdermal estradiol, LHRH agonists, Transdermal Estradiol Versus LHRH Agonists, Androgen Suppression in M0 Prostate Cancer, STAMPEDE trial.
(UroToday.com) In this presentation, Dr. Michael Morris presented the results of the phase 3 VISION trial evaluating the radiopharmaceutical lutetium-PSMA (Lu-PSMA) in patients with metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback